Generic pharma giant Viatris Inc. on Thursday announced a restructuring that will cost up to $850 million over the next three years and include shrinking its global workforce by about 10%.

An enterprise-wide review that began last year at Viatris is expected to yield between $600 million and $700 million in savings once fully implemented, most of which is expected to improve operating cash flow.

The company employed about 32,000 people in 2024, down from 45,000 employees in 2020 when Viatris, formerly known as Mylan Inc., was reincorporated in the Netherlands and relaunched. Viatris is managed from its headquarters in Cecil, Washington County, and operates a global network of about 40 manufacturing facilities across six continents.

“Today marks an important inflection point in Viatris’ evolution,” CEO Scott A. Smith said in a statement accompanying quarterly and annual financial results Thursday. “We have just completed an enterprise-wide strategic review to help make Viatris a more focused, efficient and future ready organization.”

Advertise with us

For the three months ending Dec. 31, Viatris reported total revenue of $3.7 billion, up 5% from $3.52 billion a year earlier, and adjusted gross profit of $2.10 billion, up 6% from $1.98 billion in 2024. Those results translated into adjusted earnings per share of 57 cents, up 6% from 54 cents per share in 2024.

The 12-month results included total revenue of $14.29 billion, off 3% from $14.73 billion a year ago, and adjusted gross profit of $8.05 billion, down 6% from $8.53 billion a year ago. Adjusted earnings per share for the year were $2.35, off 11% from $2.65 per share in 2024.